NEW YORK, NY / ACCESSWIRE / January 4, 2017 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Seattle Genetics, Inc. ("Seattle Genetics" or the "Company") (NASDAQ: SGEN). Such investors are advised to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/sgen.
The investigation concerns whether Seattle Genetics and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On December 27, 2016, Seattle Genetics revealed that the U.S. Food and Drug Administration ("FDA") had placed a clinical hold or partial clinical hold on some early stage trials of vadastuximab talirine, its experimental cancer drug, to evaluate the potential risk of hepatotoxicity. Seattle Genetics affirmed that six acute myeloid leukemia patients had been identified with liver toxicity and that four had died. Following this news, Seattle Genetics stock dropped $9.50 per share, or 15.36%, to close at $52.36 on December 27, 2016.
If you are aware of any facts relating to this investigation, or purchased Seattle Genetics shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/sgen. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC
ReleaseID: 452093
